CAS 839706-07-9

GNF-7

CAS : 839706-07-9

GNF-7

Degré de pureté : ≥95%

Masse moléculaire : 547.53g/mol

Ref: 54-BUP03705

N-[3-[1,4-Dihydro-1-Methyl-7-[(6-Methyl-3-Pyridinyl)Amino]-2-Oxopyrimido[4,5-D]Pyrimidin-3(2H)-Yl]-4-Methylphenyl]-3-(Trifluoromethyl)-

CAS : 839706-07-9

N-[3-[1,4-Dihydro-1-Methyl-7-[(6-Methyl-3-Pyridinyl)Amino]-2-Oxopyrimido[4,5-D]Pyrimidin-3(2H)-Yl]-4-Methylphenyl]-3-(Trifluoromethyl)-

Degré de pureté : 98+%

Masse moléculaire : 547.54g/mol

Ref: 54-PC108459

GNF-7

CAS : 839706-07-9

GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.

Formule : C₂₈H₂₄F₃N₇O₂

Degré de pureté : 97.05% - 99.7%

Couleur et forme : Solid

Masse moléculaire : 547.53

Ref: TM-T3196

GNF-7

CAS : 839706-07-9

GNF-7 is a molecule that inhibits the bcr-abl kinase, which plays a key role in chronic myelogenous leukemia (CML) and some other cancers. GNF-7 binds to the ATP binding site of the bcr-abl kinase, inhibiting its activity. It also induces caspase-independent cell death by hydrogen bond interactions with amino acids in the ATP binding site. The study has shown that GNF-7 is effective on monocytes, myeloid leukemia cells, and inflammatory bowel disease cells. GNF-7 is a small molecule that can be synthesized by chemical methods and is thus cheaper than many other cancer drugs.

Formule : C₂₈H₂₄F₃N₇O₂

Degré de pureté : Min. 95%

Masse moléculaire : 547.53 g/mol

Ref: 3D-PIB70607